DK1529047T3 - Nye purinderivater - Google Patents

Nye purinderivater

Info

Publication number: DK1529047T3
Authority: DK; Denmark
Prior art keywords: compounds; disorders; unbranched; branched; independently
Prior art date: 2002-08-15

Application number

DK03748238T

Other languages

Danish (da)

English (en)

Inventor

Peter Fischer

Bernard Nutley

Stuart Wilson

Florence Raynaud

Paul Workman

Michael Jarman

Edward Mcdonald

Original Assignee

Cyclacel Ltd

Cancer Rec Tech Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-15

Filing date

2003-08-13

Publication date

2007-03-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9942408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1529047(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-08-13 Application filed by Cyclacel Ltd, Cancer Rec Tech Ltd filed Critical Cyclacel Ltd

2007-03-19 Application granted granted Critical

2007-03-19 Publication of DK1529047T3 publication Critical patent/DK1529047T3/da

Links

229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
201000004384 Alopecia Diseases 0.000 abstract 1
229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
231100000360 alopecia Toxicity 0.000 abstract 1
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
208000015114 central nervous system disease Diseases 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000565 sulfonamide group Chemical group 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Biotechnology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)

DK03748238T 2002-08-15 2003-08-13 Nye purinderivater DK1529047T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0219054.4A GB0219054D0 (en)	2002-08-15	2002-08-15	New purine derivatives
PCT/GB2003/003554 WO2004016612A2 (en)	2002-08-15	2003-08-13	New purine derivatives

Publications (1)

Publication Number	Publication Date
DK1529047T3 true DK1529047T3 (da)	2007-03-19

Family

ID=9942408

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03748238T DK1529047T3 (da)	2002-08-15	2003-08-13	Nye purinderivater

Country Status (17)

Country	Link
US (2)	US7582642B2 (de)
EP (1)	EP1529047B8 (de)
JP (1)	JP4723858B2 (de)
CN (1)	CN1329393C (de)
AT (1)	ATE354574T1 (de)
AU (1)	AU2003267547B2 (de)
BR (1)	BRPI0313477B8 (de)
CA (1)	CA2492659C (de)
DE (1)	DE60311995T2 (de)
DK (1)	DK1529047T3 (de)
ES (1)	ES2280773T3 (de)
GB (2)	GB0219054D0 (de)
IL (1)	IL166784A (de)
MX (1)	MXPA05001843A (de)
NZ (1)	NZ538135A (de)
PT (1)	PT1529047E (de)
WO (1)	WO2004016612A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2741881B1 (fr) *	1995-12-01	1999-07-30	Centre Nat Rech Scient	Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
GB0012528D0 (en) *	2000-05-23	2000-07-12	Univ Palackeho	Triterpenoid derivatives
DE60205376T2 (de) *	2001-06-27	2006-04-06	Cyclacel Ltd.	2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
GB0219052D0 (en) *	2002-08-15	2002-09-25	Cyclacel Ltd	New puring derivatives
GB0219054D0 (en) *	2002-08-15	2002-09-25	Cyclacel Ltd	New purine derivatives
US20080125404A1 (en)	2004-08-27	2008-05-29	Cyclacel Limited	Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases
EP1951307A2 (de) *	2005-11-11	2008-08-06	Cyclacel Limited	Kombination aus einem cdk-hemmer und einem hdac-hemmer
US7560551B2 (en)	2006-01-23	2009-07-14	Amgen Inc.	Aurora kinase modulators and method of use
DK1984353T3 (en)	2006-01-23	2016-03-14	Amgen Inc	Aurorakinasemodulatorer and method of use
US7868177B2 (en)	2006-02-24	2011-01-11	Amgen Inc.	Multi-cyclic compounds and method of use
WO2008057280A1 (en)	2006-10-27	2008-05-15	Amgen Inc.	Multi-cyclic compounds and methods of use
GB0706633D0 (en)	2007-04-04	2007-05-16	Cyclacel Ltd	Combination
GB0706632D0 (en) *	2007-04-04	2007-05-16	Cyclacel Ltd	New purine derivatives
US7776857B2 (en)	2007-04-05	2010-08-17	Amgen Inc.	Aurora kinase modulators and method of use
EP2209786B1 (de)	2007-10-05	2013-02-27	Verastem, Inc.	Pyrimidinsubstituierte purinderivate
CA2716856C (en)	2008-03-20	2013-02-19	Amgen Inc.	Aurora kinase modulators and method of use
US9126935B2 (en)	2008-08-14	2015-09-08	Amgen Inc.	Aurora kinase modulators and methods of use
CA2738429C (en) *	2008-09-26	2016-10-25	Intellikine, Inc.	Heterocyclic kinase inhibitors
JP5363800B2 (ja) *	2008-12-25	2013-12-11	ライオン株式会社	育毛剤組成物
CZ302122B6 (cs) *	2009-01-28	2010-10-20	Univerzita Palackého v Olomouci	Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
WO2010114484A1 (en)	2009-04-03	2010-10-07	S*Bio Pte Ltd	Pyrimidine substituted purine compounds as kinase (s) inhibitors
GB201001075D0 (en)	2010-01-22	2010-03-10	Cyclacel Ltd	Crystalline forms
US9498471B2 (en)	2011-10-20	2016-11-22	The Regents Of The University Of California	Use of CDK9 inhibitors to reduce cartilage degradation
EP2907514B1 (de)	2014-02-17	2019-10-23	Manros Therapeutics	Purinderivatverbindungen zur medizinischen Verwendung
CA3000633C (en)	2014-10-14	2023-10-03	The Regents Of The University Of California	Use of cdk9 and brd4 inhibitors to inhibit inflammation
KR102524773B1 (ko)	2017-01-26	2023-04-21	싸이클라셀 리미티드	퓨린 유도체의 제조 방법
EP3388432A1 (de)	2017-04-10	2018-10-17	Commissariat à l'Energie Atomique et aux Energies Alternatives	Purinderivate zur verwendung als medikament und zur verwendung bei der behandlung neurodegenerativer oder neuroinflammatorischer erkrankungen
GB202000901D0 (en) *	2020-01-22	2020-03-04	Cyclacel Ltd	Process
EP3901154A1 (de) *	2020-04-23	2021-10-27	Commissariat à l'énergie atomique et aux énergies alternatives	Purinderivate als arzneimittel zur behandlung von neonataler hypoxie-ischämie-hirnverletzung und verwandten erkrankungen
CN116813621A (zh) *	2023-06-08	2023-09-29	江南大学	9h嘌呤类化合物及其药物组合物和用途
WO2026024674A1 (en)	2024-07-22	2026-01-29	Genesis Therapeutics, Inc.	Methods of treating skp2-associated cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU7296896A (en)	1995-11-01	1997-05-22	Novartis Ag	Purine derivatives and processes for their preparation
FR2741881B1 (fr) *	1995-12-01	1999-07-30	Centre Nat Rech Scient	Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) *	1996-08-02	1999-02-02	Cv Therapeutics, Incorporation	Purine inhibitors of cyclin dependent kinase 2
WO1998016528A1 (en)	1996-10-11	1998-04-23	Chiron Corporation	Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6255485B1 (en) *	1997-08-07	2001-07-03	The Regents Of The University Of California	Purine inhibitors of protein kinases, G proteins and polymerases
EP1042509A1 (de)	1997-12-24	2000-10-11	The Regents of the University of California	Verfahren durch gebrauch an oligonukleotidarrays zum suchen von neuen kinase-inhibitoren
TR200002482T2 (tr)	1998-02-26	2002-10-21	Aventis Pharmaceuticals Inc.	6,9-Diikameli 2-(Trans-(4-Aminosiklohekzil) Amino)Pürinler
HK1044334A1 (zh) *	1999-02-01	2002-10-18	Cv治疗公司	依赖细胞周期蛋白的激酶2和IκB-α的嘌呤抑制剂
US6627633B2 (en) *	1999-03-17	2003-09-30	Albany Molecular Research, Inc.	6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6969720B2 (en) *	1999-03-17	2005-11-29	Amr Technology, Inc.	Biaryl substituted purine derivatives as potent antiproliferative agents
DE60205376T2 (de) *	2001-06-27	2006-04-06	Cyclacel Ltd.	2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US6667311B2 (en) *	2001-09-11	2003-12-23	Albany Molecular Research, Inc.	Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US6812232B2 (en) *	2001-09-11	2004-11-02	Amr Technology, Inc.	Heterocycle substituted purine derivatives as potent antiproliferative agents
US20030229105A1 (en) *	2002-05-21	2003-12-11	Cyclacel Limited	Treatment of autoimmune disorders
GB0219052D0 (en) *	2002-08-15	2002-09-25	Cyclacel Ltd	New puring derivatives
GB0219054D0 (en) *	2002-08-15	2002-09-25	Cyclacel Ltd	New purine derivatives
GB0706632D0 (en) *	2007-04-04	2007-05-16	Cyclacel Ltd	New purine derivatives

2002
- 2002-08-15 GB GBGB0219054.4A patent/GB0219054D0/en not_active Ceased
2003
- 2003-08-13 JP JP2004528667A patent/JP4723858B2/ja not_active Expired - Fee Related
- 2003-08-13 PT PT03748238T patent/PT1529047E/pt unknown
- 2003-08-13 EP EP03748238A patent/EP1529047B8/de not_active Expired - Lifetime
- 2003-08-13 BR BRPI0313477A patent/BRPI0313477B8/pt not_active IP Right Cessation
- 2003-08-13 AU AU2003267547A patent/AU2003267547B2/en not_active Ceased
- 2003-08-13 ES ES03748238T patent/ES2280773T3/es not_active Expired - Lifetime
- 2003-08-13 AT AT03748238T patent/ATE354574T1/de active
- 2003-08-13 NZ NZ538135A patent/NZ538135A/en not_active IP Right Cessation
- 2003-08-13 DE DE60311995T patent/DE60311995T2/de not_active Expired - Lifetime
- 2003-08-13 CN CNB038194252A patent/CN1329393C/zh not_active Expired - Fee Related
- 2003-08-13 DK DK03748238T patent/DK1529047T3/da active
- 2003-08-13 MX MXPA05001843A patent/MXPA05001843A/es active IP Right Grant
- 2003-08-13 WO PCT/GB2003/003554 patent/WO2004016612A2/en not_active Ceased
- 2003-08-13 CA CA2492659A patent/CA2492659C/en not_active Expired - Lifetime
- 2003-08-15 GB GB0319256A patent/GB2392155B/en not_active Expired - Fee Related
2005
- 2005-01-11 US US11/033,692 patent/US7582642B2/en not_active Expired - Lifetime
- 2005-02-09 IL IL166784A patent/IL166784A/en active IP Right Grant
2009
- 2009-06-23 US US12/489,663 patent/US8846696B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU2003267547B2 (en)	2009-06-18
ES2280773T3 (es)	2007-09-16
MXPA05001843A (es)	2005-04-19
NZ538135A (en)	2007-02-23
GB0319256D0 (en)	2003-09-17
US20090325983A1 (en)	2009-12-31
DE60311995D1 (de)	2007-04-05
US20050256142A1 (en)	2005-11-17
PT1529047E (pt)	2007-03-30
EP1529047B1 (de)	2007-02-21
WO2004016612A2 (en)	2004-02-26
BRPI0313477B1 (pt)	2019-01-22
US8846696B2 (en)	2014-09-30
JP4723858B2 (ja)	2011-07-13
WO2004016612A3 (en)	2004-07-01
GB2392155B (en)	2005-03-30
BR0313477A (pt)	2005-06-21
AU2003267547A1 (en)	2004-03-03
JP2006506341A (ja)	2006-02-23
EP1529047A2 (de)	2005-05-11
DE60311995T2 (de)	2007-10-31
CN1675211A (zh)	2005-09-28
CN1329393C (zh)	2007-08-01
ATE354574T1 (de)	2007-03-15
CA2492659A1 (en)	2004-02-26
US7582642B2 (en)	2009-09-01
BRPI0313477B8 (pt)	2021-05-25
GB2392155A (en)	2004-02-25
EP1529047B8 (de)	2010-05-19
IL166784A0 (en)	2006-01-15
IL166784A (en)	2012-03-29
GB0219054D0 (en)	2002-09-25
CA2492659C (en)	2012-07-17

Publication	Publication Date	Title
DK1529047T3 (da)	2007-03-19	Nye purinderivater
GB2392156B (en)	2005-03-30	New purine derivatives
RU2361870C2 (ru)	2009-07-20	Новые кумарины, их карбоксамидные производные, способы получения, композиции и применение
CY1116119T1 (el)	2017-02-08	Παραγωγα ισοξαζολο-πυριδινης
MX2009003410A (es)	2009-07-17	Fosfoindoles enantiomericamente puros como inhibidores de vih.
HRP20241540T1 (hr)	2025-01-03	Pirolotriazinski spojevi koji djeluju kao inhibitor mnk
HUP0402454A2 (hu)	2005-03-29	Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MEP52408A (en)	2011-02-10	Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
PE20040155A1 (es)	2004-04-18	Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen
AR038814A1 (es)	2005-01-26	Compuestos de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-ona y uso en la fabricacion de medicamentos
DE602004017479D1 (de)	2008-12-11	Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
DE602005023015D1 (de)	2010-09-30	Indolderivate als viruzide
BRPI0409465A (pt)	2006-05-02	derivados de carboxamida como agentes antidiabéticos
HRP20050390A2 (en)	2006-12-31	Substituted benzoxazinones and uses thereof
RU2010107603A (ru)	2011-09-10	Производные n-(2-тиазолил)амида для лечения ожирения, диабетов и сердечно-сосудистых заболеваний
ATE487690T1 (de)	2010-11-15	2-aminobicyclo 3.1.0 hexan-2,6- dicarbonsäureesterderivat
AR054102A1 (es)	2007-06-06	Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas
CA2589438C (en)	2014-07-22	Treatment of inflammatory bowel disease
ATE135206T1 (de)	1996-03-15	Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung
AR043273A1 (es)	2005-07-27	Derivados de bifenilo, su uso, un proceso para prepararlos y medicamentos que los contienen.
AR047967A1 (es)	2006-03-15	Derivados de pirimidina utiles para tratar enfermedades de reflujo gastro-esofagico.
BG105126A (en)	2001-11-30	Tetrahydronaphthyridinyl-carboxamides have anti-convulsant activity
WO2004094396A3 (en)	2005-04-14	Dihydrothiazine prodrugs of thiazolium agents
ATE513805T1 (de)	2011-07-15	Chirale cyclische beta-aminosäuren und ihre derivate, pharmazeutische zusammensetzungen, die diese enthalten, und die verwendung dieser verbindungen